EYEG Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	10 000.00
Gjennomsnittsvolum	469.00
Markedsverdi	64.23M
EPS	$-0.420 ( 2021-11-08 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-19.65
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-02	From Stephen	Sell	250	Common Stock
2021-11-02	Mann Brenda	Sell	62	Common Stock
2021-10-04	Mann Brenda	Sell	62	Common Stock
2021-10-04	From Stephen	Sell	249	Common Stock
2021-09-02	From Stephen	Sell	253	Common Stock

INSIDER POWER
0.00
Last 98 transactions
Buy: 1 959 813 \| Sell: 207 057

EyeGate Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner
BMTC	0.948
XPDI	0.926
FATE	0.912
TCDA	0.908
GRAY	0.905
ENPH	0.896
BCAB	0.895
ODT	0.887
HECCU	0.884
LHDX	0.879

10 Mest negative korrelasjoner
TIG	-0.936
CCRC	-0.928
FRGI	-0.917
ARNA	-0.903
DSPG	-0.899
ACIW	-0.899
NTES	-0.896
EXAS	-0.896
APEN	-0.896
GGAL	-0.895

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

EyeGate Pharmaceuticals Økonomi

Annual	2020
Omsetning:	$12 059.00
Bruttogevinst:	$12.06 (0.10 %)
EPS:	$-2.54

FY	2020
Omsetning:	$12 059.00
Bruttogevinst:	$12.06 (0.10 %)
EPS:	$-2.54

FY	2019
Omsetning:	$2.69M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.23

FY	2018
Omsetning:	$1.65M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-4.50

Financial Reports:

No articles found.

EyeGate Pharmaceuticals

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.